Readiness layer for blood pressure
Measured at the right moment.
A patent-pending physiological readiness layer designed to help blood-pressure devices identify when a patient has stabilised — before the cuff inflates.
A blood-pressure reading is only as good as the moment you take it.
It is the most common measurement in medicine — around 1.3 billion adults live with hypertension, and nearly half are unaware of it.1 Yet the number is captured, every day, at the wrong moment.
The guidelines are clear. Almost nobody follows them.2
Guidelines ask for five settled minutes, no talking, repeated and averaged. In a real clinic, or a real home, that rarely happens — in one study of patients at a hypertension centre:2
Measuring before the patient has settled introduces variability — factors such as no rest period or talking can shift a reading by around 10 mmHg or more3 — enough to complicate clinical assessment. The diagnosis simply follows the number.
So we measure readiness first.
Designed to assess physiological stabilisation before the cuff inflates.
Wavescope reads the bio-signals a device already captures — an ECG or an optical PPG — and assesses whether the patient's physiology has stabilised, indicating a suitable moment to measure. No additional hardware is required.
Taken when the patient has stabilised — not the moment they happened to sit down.
Works from the signals already inside monitors and wearables.
Others optimise the measurement. We assess the moment before it.
The ECG or optical PPG your device already captures. No new sensor, no change to the cuff.
The readiness layer evaluates whether the patient's physiology has settled, continuously, in the seconds before measurement.
The host device is told when a reading is likely to be representative, and proceeds as it always has.
Delivered as software on silicon, firmware or a cloud service. Designed for OEM integration; not a standalone medical device.
The product
Software on silicon.
We don't build a device and we don't compete with the makers who do. We license the readiness layer as a component — software on silicon, firmware or a cloud service — that drops into the products the world already builds.
Built to license, not to compete.
You keep your product and your roadmap. We provide a patent-protected readiness component, backed by clinical research datasets and engineered to integrate into your regulated device roadmap — so you can offer a capability your competitors can't.
Sensor-agnostic. Hardware-neutral.
Works from ECG or optical PPG — the signals already in your monitors and wearables — delivered as a component with a reference design, backed by our semiconductor partner Microchip. Software on silicon, firmware, cloud or API, to suit your architecture.
Designed for your regulatory pathway.
Designed to support OEM submissions under FDA 510(k) (product code DXN) and EU MDR Class IIa pathways, with technical and clinical master-file documentation prepared for your file. You own the submission; we supply the evidence package.
Priced per unit, by device tier.
A per-unit licence, tiered by device class, that lets a monitor carry a readiness capability without changing its bill of materials. Commercial and reimbursement briefings are available to OEM partners on request.
A growing body of clinical research.
Two medRxiv preprints, a 2026 publication in JMIR Medical Informatics, ten independent datasets analysed to date, and a prospective clinical investigation in design.4 Summaries are provided to partners after verification.
Defensible by design
Not one patent, but a moat that compounds — a filed method patent, a growing body of clinical research, a defined regulatory strategy, and a dataset that widens with every reading.
Blood pressure is where we start.
The ability to read physiological state before a measurement reaches far beyond the cuff.
The readiness IP platform
Patent-pending BP readiness, licensed to device makers as software on a chip. Clinical investigation, FDA and CE submissions, and first licences.
Pre-clinic vital signs
Consistent, reliable vitals captured before the consultation — already piloted with University College Dublin and published in JMIR Medical Informatics.
Trusted clinical AI
Reliable inputs are the prerequisite for trustworthy clinical decision support. Today's data is tomorrow's AI.
Where we are on the road.
Clinical & regulatory roadmapmedRxiv preprint
medRxiv preprint, with UCD
Programme membership
AINM consortium, UCD-led
Peer-reviewed publication
Regulatory-grade study
PlannedMaster-file documentation
PlannedTarget
PlannedItems marked planned are targets, subject to funding, clinical results and regulatory review. Nothing on this page should be read as a claim of regulatory clearance.
Grant funding & academic collaborators
St Vincent's University Hospital
Irish Government DTIFSt Vincent's University HospitalTechnology, device & semiconductor ecosystem
Verticecloud
ObliviousMicrochipVerticecloudObliviousProgramme memberships and technology partnerships are not clinical validation of the method.
Operators, clinicians and builders.
Seán McMahon
CEO & Founder
Engineer and inventor behind the technology; 20 years in medical devices and electronics.
in
Alan Gormley
Chief Commercial Officer
Medtech commercialisation and global-standards leader; leads OEM licensing.
in
Advisory board
Clinical & OEM resource centre
Access on request · not for public distributionDetailed clinical evidence, regulatory and commercial material is provided to device manufacturers, institutional partners and qualified investors after we verify your role and organisation. Requests are logged.
Clinical evidence summary
Published pilot, preprints and the design of the prospective investigation.
PDF · updated Oct 2026 · after verificationRegulatory & master-file brief
Intended regulatory pathway and the documentation prepared for OEM submissions.
PDF · updated Oct 2026 · after verificationIntegration & reference design
Delivery options — software on silicon, firmware, cloud or API — and integration requirements.
PDF · updated Oct 2026 · after verificationCommercial & reimbursement briefing
Licensing structure by device tier and the reimbursement context in target markets.
PDF · updated Oct 2026 · after verificationLatest news
Contact
Let's talk.
For OEM licensing, clinical partnership, resource-centre access or investment — tell us who you are and we'll come back to you.